Navigation Links
Pacira Pharmaceuticals, Inc. Announces Pricing of Its Initial Public Offering
Date:2/3/2011

PARSIPPANY, N.J., Feb. 3, 2011 /PRNewswire/ -- Pacira Pharmaceuticals, Inc. (Nasdaq: PCRX), an emerging specialty pharmaceutical company, today announced the pricing of its initial public offering of 6,000,000 shares of its common stock at $7.00 per share, before underwriting discounts and commissions. All of the common stock is being offered by Pacira. The shares are expected to begin trading on the NASDAQ Global Market under the symbol "PCRX" on February 3, 2011. In addition, Pacira has granted the underwriters a 30-day option to purchase up to an additional 900,000 shares to cover over-allotments, if any.

Barclays Capital Inc. and Piper Jaffray & Co. are acting as joint book-running managers for the offering. Wedbush PacGrow Life Sciences and Brean Murray, Carret & Co. are acting as co-managers for the offering.

The offering of these securities will be made only by means of a prospectus, copies of which may be obtained from Barclays Capital Inc., c/o Broadridge Financial Solutions, at 1155 Long Island Avenue, Edgewood, NY 11717, or by calling 1-888-603-5847 or by emailing Barclaysprospectus@broadridge.com; or from Piper Jaffray & Co. at 800 Nicollet Mall, Suite 800, Minneapolis, MN 55402, by calling 1-800-747-3924.

A registration statement relating to these securities has been declared effective by the Securities and Exchange Commission.

About PaciraPacira Pharmaceuticals, Inc. is an emerging specialty pharmaceutical company focused on the development, commercialization and manufacture of novel pharmaceutical products, based on its proprietary DepoFoam® drug delivery technology, for use in hospitals and ambulatory surgery centers. The company's most advanced product candidate, EXPAREL™, a bupivacaine-based product, has completed Phase 3 clinical development for postopera
'/>"/>

SOURCE Pacira Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Positive Phase II Study of Paciras EXPAREL(TM) (DepoBupivacaine) in Total Knee Arthroplasty Presented at International College of Surgeons World Congress
2. Positive Phase II Study of Paciras EXPAREL(TM) (DepoBupivacaine) in Hernia Repair Presented at the Postgraduate Assembly in Anesthesiology (PGA)
3. Phase III Studies of EXPAREL(TM) (DepoBupivacaine) from Pacira Complete Enrollment
4. Pacira Pharmaceuticals Announces FDA Acceptance of EXPAREL™ New Drug Application for Pain Management
5. Pacira Pharmaceuticals Presents New Data from EXPAREL Phase 3 Study at Orthopaedic Research Societys 57th Annual Meeting
6. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
9. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
10. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
11. Symbollon Pharmaceuticals, Inc. Evaluates the Clinical Effects of IoGen(TM) on Fibrocystic Breast Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... CHICAGO , July 31, 2015 ... Market by Product (Moist Heat, Dry Heat, Ethylene Oxide, Filtration, ... & End User (Hospitals, Pharmaceuticals) - Global Forecast to 2020", ... reach around USD 6.1 Billion by 2020, at a CAGR ... 242 market data T ables and ...
(Date:7/31/2015)... WAYNE, Pa. , July 31, 2015 /PRNewswire/ ... a fully integrated specialty pharmaceutical company focused on ... announced the closing of its previously announced underwritten ... stock at a public offering price of $11.25 ... the offering included 1,000,000 shares issued upon the ...
(Date:7/31/2015)...  Xencor, Inc. (NASDAQ: XNCR ), a clinical-stage ... of autoimmune diseases, asthma and allergic diseases, and cancer, ... to its board of directors. ... is a tremendous asset to our board," said ... of Xencor. "Xencor faces a range of opportunities for ...
Breaking Medicine Technology:Sterilization Equipment Market is Expected to Reach USD 6.1 Billion by 2020 2Sterilization Equipment Market is Expected to Reach USD 6.1 Billion by 2020 3Sterilization Equipment Market is Expected to Reach USD 6.1 Billion by 2020 4Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 2Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 3Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 4Xencor Appoints Yujiro S. Hata to Board of Directors 2Xencor Appoints Yujiro S. Hata to Board of Directors 3
... May 6, 2011 Alexza Pharmaceuticals, Inc. (Nasdaq: ... Chief Financial Officer, August J. Moretti will present during the ... on Tuesday, May 10, 2011 at 10:00 a.m. Eastern Time. ... To access the presentation via the Web, please ...
... 6, 2011 Varian Medical Systems (NYSE: ... with Novalis® Radiosurgery program for fast and precise ... Radiosurgery Society (ISRS) congress in Paris next week. ... the capabilities of the company,s TrueBeam™ STx with ...
Cached Medicine Technology:Alexza to Present at the MDB Bright Lights Conference 2011 2Alexza to Present at the MDB Bright Lights Conference 2011 3Varian Medical Systems Spotlights Advanced Radiosurgery Systems at ISRS Congress in Paris, May 8-12 2Varian Medical Systems Spotlights Advanced Radiosurgery Systems at ISRS Congress in Paris, May 8-12 3
(Date:8/3/2015)... ... August 03, 2015 , ... ... to decline by 39 percent, according to market research compiled for the National ... from the U.S. Department of Labor, Bureau of Labor Statistics. As the number ...
(Date:8/3/2015)... ... August 03, 2015 , ... Constantin Vasilica, 48 from Romania wanted to have ... diabetes after many years of suffering and using medications with strong side effects. This ... ask for extra time off or wait longer hours in the waiting rooms. Instead, ...
(Date:8/3/2015)... ... ... The American Institute of Architects (AIA) and ... a wide range of initiatives ranging from code development and compliance to sustainability ... membership, consisting of practicing design professionals, code officials, and the building industry representatives, ...
(Date:8/2/2015)... ... 2015 , ... A new Phase I research study is looking at a ... by Kenneth G. Lucas, M.D. , chief of the division of pediatric hematology/oncology ... Kosair Children’s Hospital and in the UofL Department of Pediatrics . ...
(Date:8/1/2015)... ... , ... AlignLife Office Coordinator Heather Pugh earned the position of ... at this natural health care center in Winamac. , "Oftentimes patients are in pain ... is vital to our approach because we want to focus on the patient wants ...
Breaking Medicine News(10 mins):Health News:Dental Association Announces Impending Reduction of Dental Laboratories Could Impact Dentists 2Health News:Dental Association Announces Impending Reduction of Dental Laboratories Could Impact Dentists 3Health News:Chinese Health Care Provider Heshoutang Now Give Patients Complimentary Online Healing Options 2Health News:Chinese Health Care Provider Heshoutang Now Give Patients Complimentary Online Healing Options 3Health News:Architects, International Code Council Ink Five-Year Collaborative Agreement 2Health News:Architects, International Code Council Ink Five-Year Collaborative Agreement 3Health News:UofL Physicians Conducting Vaccine Trial for Children with Relapsed Tumors at Kosair Children’s Hospital 2Health News:New Patient Advocate Enhances Natural Health Care 2
... ... Prosynthesis Laboratories, Inc. has announced the launch of ... the Sterling, VA based nutrition company has aroused interest and invited ... “made in China”. Defying industry trends, opurity was uniquely designed and ...
... testosterone can affect quality of life, researchers say , ... young male cancer survivors often causes low energy levels ... benefit from testosterone replacement therapy, a new study suggests. ... testosterone deficiency, which is a late side effect of ...
... ... ... ... ...
... ... ... , , ... ...
... School and Queen Mary, University of London, warns that ... research could be causing pharmaceutical companies to look outside ... its most experienced researchers. The two year study focused ... that influence clinical research projects in the UK. In ...
... Medical School in Plymouth (UK), the Memorial Sloan-Kettering Cancer Center ... College in New York and the Center for Neural Tumour ... a key mechanism that makes certain cells become tumorous in ... can also occur in numbers as part of the inherited ...
Cached Medicine News:Health News:New Multivitamins Target Concern Over China's Quality Problems 2Health News:New Multivitamins Target Concern Over China's Quality Problems 3Health News:New Multivitamins Target Concern Over China's Quality Problems 4Health News:New Multivitamins Target Concern Over China's Quality Problems 5Health News:Testicular Cancer Survivors May Have Hormone Deficiency 2Health News:Guardian Brings Income Protection to New Level with Student Loan Protection Program 2Health News:Guardian Brings Income Protection to New Level with Student Loan Protection Program 3Health News:Guardian Brings Income Protection to New Level with Student Loan Protection Program 4Health News:Guardian Brings Income Protection to New Level with Student Loan Protection Program 5Health News:Pelosi Statement on President Obama's Health Insurance Reform Proposal 2Health News:New study reveals long delays and variability are losing the UK research and jobs 2Health News:Tumor mechanism identified 2
Ultra-Slip™ endotracheal tube guide for single-patient use only., ,Caution: Not MRI Compatible....
FlexiSlip™ Plastic coated malleable metal core. Single use, Sterile, Latex Free. Soft distal tip flexes to reduce risk of trauma to patient. Malleable metal core is easy to shape. Low friction ...
Slick® Disposable Endotracheal Stylet, Nylon-coated wire, Malleable core, Sureloc Stop helps maintain desired length for patient safety. Handle forming capability for better grip. Sterile. Single...
... Requires minimal cervical spine manipulation. Prevent dental ... nasally. Cost effective alternative to X-ray. Light-guided ... the soft tissues in the neck. This ... of the trachea relative to the esophagus. ...
Medicine Products: